Celecoxib

Generic Name: Celecoxib

Brand Names: Celebrex, Elyxyb, Seglentis

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₄F_₃N_₃O_₂S

CAS Number: 169590-42-5

Unique Ingredient Identifier: JCX84Q7J1L

Background: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...

Indication: Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...

Associated Conditions: Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain

Associated Therapies: -

Clinical Trials

Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Stage IV Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: celecoxib
Other: laboratory biomarker analysis

First Posted Date: 2003-06-06

Last Posted Date: 2013-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00062101

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma

Phase 1

Completed

Conditions: Liver Cancer

First Posted Date: 2003-04-09

Last Posted Date: 2012-06-11

Lead Sponsor: Northwestern University

Target Recruit Count: 8

Registration Number: NCT00057980

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer
Lung Cancer

First Posted Date: 2003-04-09

Last Posted Date: 2012-06-11

Lead Sponsor: Northwestern University

Registration Number: NCT00058006

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Rush Cancer Institute at Rush University Medical Center, Chicago, Illinois, United States

and more 1 locations

Celecoxib in Preventing Lung Cancer in Former Heavy Smokers

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Other: placebo
Drug: celecoxib

First Posted Date: 2003-03-07

Last Posted Date: 2011-06-20

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 112

Registration Number: NCT00055978

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: celecoxib

First Posted Date: 2003-03-07

Last Posted Date: 2017-02-15

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 110

Registration Number: NCT00056082

Locations: 🇺🇸
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸
Lynn Sage Comprehensive Breast Center at Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States

Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00006381

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Celecoxib
Drug: Docetaxel

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-29

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 34

Registration Number: NCT00030407

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Celecoxib in Preventing Skin Cancer

Phase 2

Withdrawn

Conditions: Non-melanomatous Skin Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-22

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00025051

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States

Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome

Phase 2

Completed

Conditions: Non-melanomatous Skin Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-26

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 60

Registration Number: NCT00023621

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States

Celecoxib in Preventing Cancer in Patients With Rectal Polyps or Colorectal Neoplasia

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00043043

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
National Naval Medical Center, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy